A recent preclinical study showed that an antibody-drug conjugate (ADC) construct using monomethyl auristatin E (MMAE) coupled with an anti-TEM8 antibody could successfully induce an effective and dose-dependent anti-tumor response (4). This evidence concerns the gene ANTXR1 and neoplasm.